Displaying 13 - 24 of 82
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
1

GSK: Unlocking the genetic architecture of Steatotic Liver Disease. A new paradigm in patient management (Complete Session) - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
1

GSK: Meet the Experts - Genetic architecture of Steatotic Liver Disease (Complete Session) - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
3

Novo Nordisk: Navigating MASH patient care - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
3

Novo Nordisk: Navigating MASH patient care - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
3

Novo Nordisk: Navigating MASH patient care - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Unfolding the metabolic dysfunction of MASH: exploring the pathophysiology and outcomes - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Unfolding the metabolic dysfunction of MASH: exploring the pathophysiology and outcomes - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Unfolding the metabolic dysfunction of MASH: exploring the pathophysiology and outcomes - EASL Congress 2024

View
Displaying 13 - 24 of 82